Milestone (MIST) Q2 2026 Earnings Call Transcript

Milestone (MIST) reported Q2 2026 progress tied to the first full quarter of the CARDAMYST commercial launch, during an Aug. 12, 2026 earnings call. Product revenue reached $559,000, with first-half product revenue of $797,000, reflecting about 4.5 months of market promotion. Total prescriptions rose to 1,200 in Q2 from about 300 in Q1, while unique prescribers climbed to 600 and patient volume to 1,000. Cash and investments totaled $170.6 million at June 30, 2026, up from $106 million at end-2025, and management said runway extends into the second half of 2027. The company posted a $28.6 million net loss for the quarter. Forecasts also included Medicare coverage starting in 2027 and an EMA decision window for etripamil in early 2027.